<i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Nicholas T. Younger(Institute of Genetics and Cancer), Luke Boulter(MRC Institute of Genetics and Molecular Medicine), Anabel Martinez Lyons(Institute of Genetics and Cancer), David H. Wilson(University of Zimbabwe), Konstantinos Gournopanos(Institute of Genetics and Cancer), Edward J. Jarman(Western General Hospital), Peter A. Tennant(Institute of Genetics and Cancer), Graeme R. Grimes(Institute of Genetics and Cancer), Pleasantine Mill(University of Edinburgh), Stephen J. Wigmore(Queen's Medical Centre), Timothy J. Kendall(MRC Centre for Regenerative Medicine), Alison Meynert(Institute of Genetics and Cancer), Scott H. Waddell(Edinburgh Cancer Research), Duncan Sproul(Edinburgh Cancer Research), Rachel V. Guest(Edinburgh Royal Infirmary), Martin S. Taylor(Institute of Genetics and Cancer), Juan Carlos Acosta(Edinburgh Cancer Research), Mollie L. Wilson(Institute of Genetics and Cancer)
Cited by 17
Related Papers
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
|Nature Medicine|2017|1.5k
Primary cilia as dynamic and diverse signalling hubs in development and disease
|Nature Reviews Genetics|2023|386
WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited
|Journal of Clinical Investigation|2015|274
Genetic heterogeneity in Cornelia de Lange syndrome (CdLS) and CdLS-like phenotypes with observed and predicted levels of mosaicism
|Journal of Medical Genetics|2014|171